Aprea logo 445pt.png
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
09 nov. 2022 16h15 HE | Aprea Therapeutics
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Aprea logo 445pt.png
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
22 sept. 2022 18h00 HE | Aprea Therapeutics
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
08 sept. 2022 08h00 HE | Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...